The Department of Justice has proposed sweeping legislation aimed at banning what it describes as “chemical or surgical mutilation” of children receiving gender-affirming care, marking a significant escalation in the federal government’s approach to transgender healthcare for minors.
The Victims of Chemical or Surgical Mutilation Act (VCSMA), transmitted to Congress this week, would prohibit healthcare professionals from performing certain medical procedures on transgender youth and create a private right of action for affected children and their parents. The legislation, led by Representative Bob Onder (R-MO) and Senator Marsha Blackburn (R-TN), represents the DOJ’s most aggressive step yet in a months-long campaign targeting providers of gender-affirming care across the country.
A Multi-Pronged Federal Approach
“The Department of Justice has heard from far too many families who have been devastated by mutilative medical procedures that fly in the face of basic biology,” Attorney General Pamela Bondi stated when announcing the proposal. “While we continue our ongoing legal battle to protect children, we appreciate our colleagues in Congress who are working diligently alongside us to end these abusive procedures once and for all.”
The legislative push comes as part of a broader strategy. Since April, the DOJ has been pursuing investigations against providers under multiple federal statutes, including the False Claims Act (FCA), the Food, Drug, and Cosmetic Act (FDCA), and laws originally designed to ban female genital mutilation. These efforts stem from an April 22 memo from Attorney General Bondi entitled “Preventing the Mutilation of American Children,” which directed the department to pursue claims against healthcare providers who allegedly “miscode” or “misbill” gender-affirming treatments.
What exactly does this mean for providers? The Civil Division of the DOJ has made it clear they will “investigate and pursue those submitting false claims in connection with drugs or services—including puberty blockers, hormones, or surgery—used to facilitate a child’s gender transition,” according to documents outlining the division’s 2025 priorities.
States Push Back
The federal actions haven’t gone unchallenged. A coalition of state attorneys general has filed suit against the federal government, arguing that the DOJ’s interpretation of existing laws represents an overreach of federal authority and an infringement on states’ rights under the Tenth Amendment.
The lawsuit specifically challenges the application of female genital mutilation statutes to gender-affirming care, pointing out that the original law contains exceptions for medical care provided by licensed physicians. The complaint also contests the characterization of gender-affirming treatments as “inherently fraudulent” under the False Claims Act.
Is this a case of federal overreach? Critics certainly think so. The coalition argues that accurately billing for medically necessary healthcare cannot constitute fraud simply because the current administration disagrees with the treatment approach.
Medical Community Divided
The DOJ’s actions, guided by Executive Order 14187 (“Protecting Children from Chemical and Surgical Mutilation”), also focus on the labeling and marketing of drugs used in gender transition, targeting what the administration characterizes as misleading information about the effects of gender-affirming healthcare.
But many medical experts resist the conflation of gender-affirming care with mutilation. Research shows that gender-affirming care “significantly improves mental health outcomes, reduces risk of suicide, and enhances quality of life among transgender youth,” according to a policy brief from Equality Now published last month.
The brief emphasizes that gender dysphoria is a recognized clinical condition and that treatments for minors involve multi-disciplinary review, including psychological evaluations to determine the child’s best interests.
The DOJ’s legislative proposal now heads to Congress, where it faces an uncertain future. But regardless of its legislative fate, the administration’s multi-pronged enforcement strategy signals a fundamental shift in how federal authorities approach the controversial issue of gender-affirming care for transgender youth.
“We will use every tool at our disposal,” Attorney General Bondi has promised — and so far, that appears to be exactly what’s happening.
